CClinicalTrials.gg
Status unknownNCT03231956CLEAR SepsisUpdated Mar 18, 2020

CLEAR Sepsis Clinical Study

An observational study in Sepsis, sponsored by Edwards Lifesciences. Status unknown at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Edwards Lifesciences · Observational

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
182
Ages
18 Years and older
Sex
All
01

Study summary

To investigate the relationship between initial ClearSight™ derived hemodynamic parameters and outcomes (death, ongoing organ dysfunction or delayed ICU admission) in patients with acute infection and possible sepsis, with a focus on venous blood lactate (\< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dL) and hemodynamic subgroups, using ED patients presenting with minor infections or asthma/COPD exacerbations as controls (henceforth referred to as Sepsis Mimic Group).

02

Conditions studied

  • Sepsis

Browse trials for

03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's planned enrollment of 182 is above the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Edwards Lifesciences is the lead sponsor of 124 studies on the registry; 19 are open to participants now.

Of its 34 completed or terminated interventional studies of FDA-regulated products, 32 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with acute infection and possible sepsis, with a focus on venous blood lactate (\< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dL) and hemodynamic subgroups, using ED patients presenting with minor infections or asthma/COPD exacerbations as controls (henceforth referred to as Sepsis Mimic Group).

Eligibility criteria

Venous Blood Lactate Groups

Inclusion Criteria:

  • ≥ 18 years of age at the time of enrollment
  • Any combination of acute symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection
  • ED Physician confirms likely hospital admission (> 50%) due to suspicion of infection
  • ED Physician confirms intention to order both blood cultures and venous blood lactate levels
  • Ability to enroll patient and begin ClearSight™ monitoring within three (3) hours of ED presentation

Exclusion Criteria:

  • Initial venous blood lactate measured > 3 hours after ED arrival
  • Pre-existing infection for which patient is being treated with antibiotics as an outpatient
  • Prisoners
  • Pregnant women
  • Any previous medical condition with life expectancy of \< 3 months (patients with ESRD and heart failure are not excluded)
  • DNR or comfort care order preexisting to ED visit or established in the ED
  • Palliative care or hospice consult in the ED
  • Known severe aortic insufficiency
  • Known history of Raynaud's disease
  • Poor follow-up candidate in the opinion of the Investigator
  • Current or planned enrollment in an investigational trial that in the opinion of the Investigator may significantly affect hemodynamic data collection.

Control Sepsis Mimic

Inclusion Criteria:

  • ≥18 years of age at the time of enrollment
  • Presents to the ED with a chief complaint consistent with a minor infection (upper respiratory infection, soft tissue infection, viral infection) or an asthma or COPD exacerbation on whom the treating physician is not ordering labs for blood cultures or lactate levels
  • Ability to enroll patient and begin ClearSight™ monitoring within three (3) hours of ED presentation.

Exclusion Criteria:

  • Pre-existing infection for which patient is being treated with antibiotics as an outpatient
  • Prisoners
  • Pregnant women
  • Any previous medical condition with life expectancy of \< 3 months (patients with ESRD and heart failure are not excluded)
  • DNR or comfort care order preexisting to ED visit or established in the ED
  • Palliative care or hospice consult in the ED
  • Known severe aortic insufficiency
  • Known history of Raynaud's disease
  • Poor follow-up candidate in the opinion of the Investigator
  • Current or planned enrollment in an investigational trial that in the opinion of the Investigator may significantly affect hemodynamic data collection.
  • Treating physician is planning on ordering either a lactate or blood cultures on the patient.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
182 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 0

    Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.

    Device: ClearSight™ / EV1000NI Clinical Platform

  • Group 1

    Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL

    Device: ClearSight™ / EV1000NI Clinical Platform

  • Group 2

    Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL

    Device: ClearSight™ / EV1000NI Clinical Platform

  • Group 3

    Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL

    Device: ClearSight™ / EV1000NI Clinical Platform

Interventions

  • DeviceClearSight™ / EV1000NI Clinical Platform

    Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System

06

What researchers measure

Primary outcomes

  1. Composite outcome

    Increase in modified Sequential Organ Failure Assessment (mSOFA) score ≥ 1 resulting in ICU admission / death.

    Time frame: Within 72 hours of presentation

  2. Venous Blood Lactate clearance

    Venous Blood Lactate clearance

    Time frame: Within 24 and 72 hours of presentation

  3. Length of Stay

    Emergency Department length of stay, ICU length of stay, and Hospital length of stay

    Time frame: 30 days

  4. Recidivism

    Recidivism within 30 days of the index hospital visit

    Time frame: 30 days

07

Study locations

3 of 5 sites recruiting
  • Detroit Receiving Hospital
    Detroit, Michigan 48201, United States
    Recruiting
  • Sinai-Grace Hospital
    Detroit, Michigan 48235, United States
    Recruiting
  • Ascension St. John Hospital
    Detroit, Michigan 48236, United States
    Recruiting
  • Beaumont Hospital, Royal Oak
    Royal Oak, Michigan 48703, United States
    Terminated
  • Beaumont Hospital, Troy
    Troy, Michigan 48085, United States
    Terminated
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03231956
Lead sponsor
Edwards Lifesciences
Responsible party
Sponsor
First posted
Jul 27, 2017
Start date
Jun 29, 2017
Primary completion
Dec 31, 2021 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Mar 18, 2020

Study contacts

Jurandir Araujo, BA
Contact
jurandir_araujo@edwards.com
949-250-5469
Ryan Zafra, BS
Contact
ryan_zafra@edwards.com
949-250-1354

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion